QPPV.COM KNOWLEDGE ASSESSMENT

WHO Smart Pharmacovigilance: What WHA79.11 Means for Global Safety Systems

Test your understanding of the concepts covered by WHO Smart Pharmacovigilance: What WHA79.11 Means for Global Safety Systems.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which communication best reflects the article’s approach to pharmacovigilance risk communication?

State the recommended action without discussing evidence limitations, to avoid confusing the audience. Describe the evidence, its limitations and uncertainty, its clinical meaning, and any action needed. Wait until uncertainty is eliminated before communicating any safety information. Focus on reassuring language and omit how new information will be assessed.

Question 2 of 10 A national authority uses another regulator’s safety assessment to support its own review. Which description best captures the concept of reliance as presented in the article?

It is automatic adoption of another regulator’s conclusion, without considering local context. It can reduce duplication while the relying authority retains responsibility for local decisions and considers relevant context. It transfers all legal accountability from the relying authority to the authority whose work is used. It is appropriate only when both authorities have identical laws and patient populations.

Question 3 of 10 A global safety system exchanges case data rapidly, but no one monitors whether data become incomplete or inconsistent at system boundaries. Which improvement most directly addresses the weakness?

Measure data quality across interfaces, including completeness, consistency, provenance and timeliness. Increase the number of exchanged fields without assessing their meaning. Replace all local systems with a single global platform. Focus quality control only on the final safety database.

Question 4 of 10 A safety database passes case-level quality checks, but recurring errors arise when data are transferred from a patient-support programme. What is the most appropriate quality-system response?

Assess the interface and source process, determine the impact, and address the root cause rather than relying only on database-level checks. Repeat the database checks more frequently without reviewing the transfer process. Exclude all patient-support information from pharmacovigilance. Close the issue if no individual case has yet led to a confirmed signal.

Question 5 of 10 A company’s epidemiological study uses a large database but has uncertain outcome definitions, incomplete follow-up and limited control of confounding. What conclusion best reflects the role of real-world evidence?

The study is reliable because real-world data are inherently representative. The study’s value depends on its design and data fitness; size alone does not resolve bias or measurement limitations. The study can replace all other pharmacovigilance evidence because it is post-authorisation. The study should be treated as equivalent to a spontaneous report because both are observational.

Question 6 of 10 A regulator has access to experienced signal assessors but lacks epidemiological and data-governance expertise for increasingly complex evidence. Which capacity response is most consistent with WHA79.11’s systems perspective?

Invest in multidisciplinary workforce capability matched to the safety questions the system must answer. Replace specialist training with automated analytics. Limit safety assessment to spontaneous-report review, which requires no additional expertise. Focus capacity building only on database administration.

Question 7 of 10 A manufacturer combines spontaneous reports with an epidemiological study in a safety review. Which practice best preserves the value of both evidence streams?

Treat the report count and study estimate as directly interchangeable measures. Use each source according to its strengths and limitations, explaining how they contribute to the safety question. Discard spontaneous reports once an epidemiological study is available. Give the study priority in every case because quantitative evidence is always stronger.

Question 8 of 10 A company plans to purchase an AI platform before identifying the safety problem it is intended to address. Which alternative approach is most consistent with the implementation sequence described in the article?

Map the safety ecosystem, define the question, assess data fitness and governance needs, then consider suitable advanced methods. Select the platform with the broadest features and adapt the safety question to its outputs. Deploy the platform first and determine its intended use from early results. Avoid mapping sources because advanced analytics can discover all relevant data automatically.

Question 9 of 10 A company is documenting an action as legally required specifically by WHA79.11, even though no applicable EU or national instrument has been identified. What is the most appropriate corrective step?

Retain the claim because WHO resolutions automatically create equivalent duties in every jurisdiction. Distinguish the resolution’s policy direction from the binding source of the obligation, and identify the applicable legal or regulatory basis. Remove all reference to WHA79.11 from company materials because it has no practical relevance. Convert the action into a marketing-authorisation condition internally.

Question 10 of 10 A pharmacovigilance team deploys a model trained on data from a narrow population in a substantially different setting. Which issue should be assessed particularly carefully?

Whether the model’s training and evaluation data are representative enough for the intended use and whether performance or bias changes across populations. Whether the model can eliminate the need for source-data quality controls. Whether the model’s output can be accepted without auditability if it is commercially supplied. Whether the model can be exempted from change control because its underlying algorithm is unchanged.

WHO Smart Pharmacovigilance: What WHA79.11 Means for Global Safety Systems

Cookie Settings